“…Plasmid/viral vectors encoding miRs are encouraging strategies to replace miRs in vivo, with good transduction efficiency and minimal toxicity (Brown et al, 2006, Colin et al, 2009). Therefore, the development of miR-based therapeutics is of great interest in various diseases (Banno et al, 2014, Boon et al, 2013, Ge et al, 2014, Kornfeld et al, 2013, Sun et al, 2012). In the present study, we found that miR-146b expression was significantly decreased in IL-10 deficient mice with colitis, which prompted us to test miR-146b mimic in the treatment of colitis in IL-10 −/− mice.…”